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Glabellar tap or reflex (GR) is an old bedside clinical test used in the diagnostics of 
Parkinson’s disease (PD), but its diagnostic value is unclear. This study examines the 
diagnostic validity and reliability of GR in PD in relation to brain dopaminergic activity. 
 
GR was performed on 161 patients with PD, 47 patients with essential tremor (ET) and 40 
healthy controls immediately prior to dopamine transporter (DAT) [123I]FP-CIT SPECT 
scanning. The binding ratios were investigated with consideration of the GR result 
(normal/abnormal). Additionally, the consistency of the GR was investigated with 89 patients 
after a mean follow-up of 2.2 years. 
 
PD and ET patients had higher GR scores than healthy controls (p<0.001), but there was no 
difference in GR between PD and ET patients (p=0.09). There were no differences in the ratio 
of abnormal to normal GRs between the PD and ET groups (73% vs 64% abnormal, 
respectively, p=0.13) or in DAT binding between PD patients with abnormal and normal GRs 
(p>0.36). Over follow-up, the GR changed from abnormal to normal in 20% of PD patients 
despite the presence of clinically typical disease. The sensitivity and specificity of GR for 
differentiating PD from ET were 78.3% and 36.2%, respectively. 
 
Although GR has been used by clinicians in the diagnostics of PD, it does not separate PD 
from ET. It also shows considerable inconsistency over time, and abnormal GR has no 
relationship with dopamine loss. Its usefulness should be tested for other clinical diagnostic 
purposes. 
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Glabellar tap or reflex (GR) is an old bedside clinical test used in the diagnostics of 
Parkinson’s disease (PD), but its diagnostic value is unclear. This study examines the 
diagnostic validity and reliability of GR in PD in relation to brain dopaminergic activity. 
 
Methods: GR was performed on 161 patients with PD, 47 patients with essential tremor (ET) 
and 40 healthy controls immediately prior to dopamine transporter (DAT) [123I]FP-CIT SPECT 
scanning. The binding ratios were investigated with consideration of the GR result 
(normal/abnormal). Additionally, the consistency of the GR was investigated with 89 patients 
after a mean follow-up of 2.2 years. 
 
Results: PD and ET patients had higher GR scores than healthy controls (p<0.001), but there 
was no difference in GR between PD and ET patients (p=0.09). There were no differences in 
the ratio of abnormal to normal GRs between the PD and ET groups (73% vs 64% abnormal, 
respectively, p=0.13) or in DAT binding between PD patients with abnormal and normal GRs 
(p>0.36). Over follow-up, the GR changed from abnormal to normal in 20% of PD patients 
despite the presence of clinically typical disease. The sensitivity and specificity of GR for 
differentiating PD from ET were 78.3% and 36.2%, respectively. 
 
Conclusions: Although GR has been used by clinicians in the diagnostics of PD, it does not 
separate PD from ET. It also shows considerable inconsistency over time, and abnormal GR 







The glabellar reflex (GR), also known as the glabellar tap sign, is an old clinical examination 
test first described by Dr. Walker Overend in 1896 (Overend 1896). No exact description of 
the maneuver has been established, but it is typically performed by the examiner gently 
tapping an index finger on the patient’s glabellar region, located between the eyebrows, after 
which a possible blink reflex is observed (Pearce et al. 1968). The traditional hypothesis 
states that healthy individuals quickly habituate to the stimulus, thus terminating the reflex 
after a few blinks or sometimes not blinking at all. 
 
Overend did not describe in detail the mechanism underlying his hypothesis of the primitive 
reflex, but ever since it has been used by many neurologists as a simple diagnostic test for 
parkinsonian syndromes. Some neurologists have included the GR test in their routine 
neurological examination due to its potential value in supporting the diagnosis of Parkinson’s 
disease (PD). A number of studies have suggested that an abnormal test result may occur 
particularly in PD (Rushworth 1962; Jensen et al. 1983; Vreeling et al. 1993; Garland 1952), 
but an abnormal GR has also been described in numerous other conditions (Pearce et al. 
1968; Jensen et al 1983; Thomas 1994). However, no research examining GR in relation to 
brain dopamine function – or any other biomarkers, for that matter – has been performed. 
 
If an abnormal GR was associated with an abnormal PD-related biomarker, such as striatal 
dopamine transporter (DAT) binding, it would support its use in clinical practice. On the other 
hand, if the test had suboptimal specificity between degenerative and non-degenerative 
parkinsonisms, and no association with striatal DAT binding, it would question the rational use 






Previous research in this field has mainly been conducted with small samples, which could 
contribute to the inconsistency. A study with 100 participants indicated that further research 
with larger sample sizes was needed to examine the relationship between GR and 
parkinsonian disorders (Brodsky et al. 2004). Therefore, in this study, we investigated the 
relationship of GR and presynaptic striatal dopamine function and compared the results in a 
real-life sample of 248 patients with clinically unclear parkinsonian syndromes (CUPS), who 
were referred for diagnostic brain DAT imaging. In addition, a subsample of patients was re-









The flowchart of patients is presented in Figure 1. The prospective study included 161 
patients with PD, 47 patients with ET and 40 healthy controls. The GR test and dopamine 
transporter (DAT) [123I]FP-CIT SPECT were performed for each participant on the same day. 
The patients were clinically investigated 2–4 hours before SPECT scanning (NMDAT 
study; ClinicalTrials.gov identifier: NCT02650843). In addition to GR, the examination 
included a clinical interview, the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) 
part III, the Mini-Mental State Examination (MMSE) and the Beck Depression Inventory (BDI). 
All examiners successfully completed the MDS-UPDRS Training Program and Exercise. 
Patients with an MMSE score less than 18 were excluded from the study. 
 
Patients with PD and ET were scanned with [123I]FP-CIT SPECT for clinical diagnostic 
purposes at Turku University Hospital or Helsinki University Hospital Medical Imaging Center, 
Finland, during the years 2014–2020. After a mean clinical follow-up period of 3.1 years (SD 
1.5) after DAT imaging, the final clinical diagnoses of the patients (PD or ET) were 
established based on full patient histories, including medication response, symptoms, signs, 
laboratory results and imaging results. 
 
Healthy controls were scanned using the same protocol, and each control participant 
underwent the same clinical examinations. To investigate the consistency of GR test results 
over time, 89 (PD n=71, ET n=18) patients were re-examined with GR and other clinical tests 






The study was approved by the Ethics Committee of the Turku Hospital district and was 
conducted according to the principles of the Declaration of Helsinki. Written informed consent 
was obtained from all participants included in the study. 
 
Glabellar reflex 
Overend set the cutoff point for normality at three blinks, but varying cutoff points for a normal 
result have been suggested: the Simpson-Angus Scale drew the line at five blinks (Simpson 
and Angus 1970) whereas in another study, ten or fewer blinks was considered a normal 
result (Rao et al. 2003). We used a previously described protocol in which twenty-one 
consecutive, evenly paced taps were performed on the participant’s glabellar region with an 
approximate frequency of two taps per second (Simpson and Angus 1970). If no reflex was 
observed after three taps, the test was discontinued, and the result was considered normal. 
The examination was explained to the patient prior to its execution, and special attention was 
given to the positioning of the examiner and his or her index finger: the test was performed 
with the index finger pointing downwards and the examiner standing parallel to the patient to 
prevent the reflex from being evoked by a shadow or a visual threat. In accordance with the 
original description, twitching of the lower eyelids after the stimulus was registered, as was 
possible habituation to the stimulus (Overend 1896). Three twitches or fewer was considered 
a normal response and physiological habituation, whereas four twitches or more was 
considered an abnormal result.  
 
Imaging and image analysis 
SPECT imaging started three hours after the 185-MBq injection of [123I]FP-CIT. Potassium 
perchlorate (250-300 mg) or Jodix™ tablets (130 mg) were given 30-60 minutes before the 





acquired using one of our eight SPECT/CT devices. To allow data comparisons, all the 
SPECT/CT devices were calibrated using a striatal phantom (RSD, Radiology Support 
Devices, Inc., Long Beach, USA) before the study. The calibration procedure followed the 
guidance of Hermes Medical Solutions (Diemling 2012) and Tossici-Bolt et al. (2011). The 
SPECT data were reconstructed using the 3D OSEM algorithm with attenuation, collimator 
response and scatter corrections (HybridRecon Neurology, version 1.3, Hermes Medical 
Solutions AB, Stockholm, Sweden). The acquisition and reconstruction protocols were the 
same for all our devices and were based on EANM recommendations (Darcourt et al. 2010) 
Reconstructed images were analyzed using BRASS semiautomated analysis software 
(version 2.6, Hermes Medical Solutions, Stockholm, Sweden). Scanner-specific corrections 
based on our calibrations were used for the BRASS analyses (Diemling 2012; Tossici-Bolt et 
al. 2011; Varrone et al. 2013). Specific binding ratios (SBRs) for six regions (left and right 
caudate, anterior putamen and posterior putamen) were calculated using the occipital cortex 




For comparisons among three groups, ANOVA or Kruskal-Wallis tests were used, followed by 
pairwise testing with Tukey’s test or Bonferroni’s corrections. For comparisons between two 
groups, independent samples t-tests, Mann-Whitney U tests or chi-square tests were used. 
Analysis of covariance (ANCOVA), adjusted for motor symptom severity, age and scanning 
device, was used to compare groups of PD patients with normal and abnormal GR results. 
GR results and established clinical diagnosis were available for all patients. The level of 
statistical significance was set at p<0.05. IBM SPSS Statistics (version 27, SPSS, Inc., 






Demographic and clinical characteristics are presented in Table 1. Compared to the healthy 
individuals, both the PD and ET patients had higher (abnormal) GR scores (p<0.001) (Figure 
2A). There were no differences between the PD and ET patients in GR scores (p=0.09). 
There was no difference in the ratio of abnormal/normal GRs between the PD and ET patients 
(Table 1). The same was true whether the cutoff for abnormality was set at 5 (p=0.14) or 10 
(p=0.09). Compared to the HC and ET patients, the PD patients had clearly lower striatal DAT 
binding values (62.4% lower mean posterior putamen SBR in PD vs. ET, p<0.001) (Figure 
2B). A similar difference was observed for the caudate nucleus and anterior putamen (Table 
1). The severity of motor symptoms in the PD patients and ET patients was comparable 
(p=1.0), although the symptom duration in ET patients was longer (Table 1). 
 
The sensitivity and specificity of GR for differentiating between PD and ET were 78.3% and 
36.2%, respectively. PD patients with an abnormal GR result had higher MDS-UPDRS motor 
scores and lower striatal DAT binding than PD patients with normal GR results (Table 2). 
When motor MDS-UPDRS, age and devices were used as covariates in the ANCOVA, there 
were no differences in DAT binding in any of the studied brain regions between patients with 
abnormal and normal GRs (p>0.36). In both the ET and the HC group, there were no 
differences in DAT binding in any of the studied brain regions between those who had 
abnormal GR values and those with normal values (p>0.21). 
 
In the follow-up cohort of 71 PD patients and 18 ET patients, the GR changed from abnormal 
to normal in 14 PD patients (20%) and in 7 ET patients (39%) over a mean period of 2.2 







The present study shows that the GR test has suboptimal specificity for distinguishing PD 
from ET and no association with striatal DAT binding, questioning the rational use of GR as 
part of the clinical examination of a patient with suspected PD. Our study focused on PD and 
ET, two conditions that can be difficult to differentiate in early stages and whose differentiation 
is the official indication for clinical brain DAT imaging (FDA 2015; EMA 2017). The results 
show that (1) GR has suboptimal diagnostic value for PD with reference to ET and (2) when 
the effects of symptom severity and age are used as covariates, there is no relationship 
between GR and striatal DAT function in patients with PD, patients with ET or healthy 
controls. 
 
The sensitivity and specificity of GR for differentiating between PD and ET were 78.3% and 
36.2%, respectively, demonstrating that in clinical practice at bedside, GR produces a high 
number of both false positive and false negative findings. Previous studies have suggested 
that GR may be abnormal in individuals with other diseases and conditions, including 
Alzheimer’s disease, aging, hydrocephalus, HIV encephalopathy, schizophrenia, diffuse 
axonal injury, brain tumors, encephalitis, severe cerebral anoxia, presenile dementia and 
subarachnoid hemorrhagia (Pearce et al. 1968; Jensen et al. 1983; Thomas 1994; Formisano 
et al. 2009). Even in migraine, a marked proportion of patients may show no habituation in 
GR (Jensen et al. 1983). Our DAT findings further showed that there were no differences in 
presynaptic dopaminergic function between individuals with normal and abnormal GRs. This 
was also true for patients with PD when the effects of aging and motor symptom severity were 
controlled for. Therefore, abnormal GR appears to be associated with advanced disease 
stage and older age in PD, but it has no independent relationship with central dopamine loss. 





the extent that a normal DAT scan is an exclusion criterion of PD (Postuma et al. 2015). It is 
important to note, however, that before correction for multiple comparisons, the difference in 
the abnormal/normal GT ratio between PD and ET was borderline significant, which suggests 
that there may be an underlying difference, albeit one that is insufficient for clinical diagnostic 
use. Indeed, in the follow-up segment of our study, we further observed considerable 
intraindividual variation in the GR, which underlines the ambiguity and lack of consistency of 
the GR as a diagnostic test. 
 
If GR has no major clinical role in the differential diagnosis of degenerative parkinsonism, and 
if it is not linked to dopamine loss, the question remains regarding its mechanism and 
feasibility in clinical neurology. It is possible that blink reflex habituation and measurements 
have diagnostic value and clinical relevance for other conditions, such as primary dementing 
disorders (Mohammadian et al. 2015), headache syndromes (Avramidis et al. 2017), multiple 
sclerosis (Brooks et al. 2015), Bell’s palsy (Syed et al. 1999), or psychotic disorders 
(Taiminen et al. 2000). However, further studies with large samples in these diagnostic 
groups are needed. 
 
One should also note that MDS-UPDRS motor scores were high also in ET patients 
suggesting that ET phenotypes were in many cases ET plus (Bhatia et al. 2018) which could 
be pathophysiologically different as compared to typical cases of purely tremolous ET. 
Additionally, the high scores of ET patients underline the potential phenotypic overlap of ET 
and PD. In our study the concept of overlap is also supported by equal GR scores in both 
groups (p=0.09) and high BDI scores of both PD and ET patients compared to healthy 





very challenging, and the clinical picture of both conditions can resemble that of the other at 
different stages of the illness (Algarni et al. 2017). 
 
It is also of relevance to note that, in PD, previous kinematic studies have documented normal 
velocity and amplitude of the closing and opening phases during voluntary blinking, but 
increased duration of the pause between the opening and closing phases (inter-phase pause) 
(Agostino et al. 2008). On the other hand, during reflex blinking, the kinematic parameters or 
the length of the inter-phase pause appear to be similar in PD patients and healthy controls 
(Agostino et al. 2008). These and other findings indicate that the brainstem circuits of the 
blink reflex are generally preserved in PD (Bologna et al. 2013), and the miscoordination of 
the timing and reciprocity of the muscles required for blinking are primarily caused by the 
impaired basal ganglia and interconnected cortical structures in PD (Agostino et al. 2008). 
The role of the basal ganglia is supported by evidence suggesting that spontaneous blinking 
can be increased with subthalamic nucleus deep brain stimulation (Bologna et al. 2012) and 
dopaminergic replacement therapy (Karson 1983). 
 
The reliability of our results is supported by the large sample size, the use of DAT imaging 
and the clinical follow-up. The study is limited by the lack of neuropathological diagnostic 
verification, a common problem in most PD neuroimaging studies, and the use of several 
scanning sites with different SPECT/CT devices. However, the devices were intercalibrated, 
and the results were similarly nonsignificant whether device was or was not included as a 
covariate in the analysis. The somewhat higher DAT binding in ET patients compared to 
healthy controls could be associated with a self-selection bias in the control group (patients 





a selection bias in the ET group (patients with mild DAT defects were excluded). The 
difference, however, had no effect on the primary results. 
 
In summary, the present study shows that the accuracy of the glabellar tap test in the 
diagnosis of PD is suboptimal, and the test results are inconsistent over time. The usefulness 
of the GR should be tested for other clinical diagnostic purposes, but it does not seem to 
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Table 1 Demographic and clinical characteristics of PD and ET patients compared to 
healthy individuals (HCs); values are means (SD), median [IQR], n or %. 
 










n = 248 161 47 40 - - 
Age (years) 64.5 (10.0) 65.4 (10.1) 66.8 (9.0) 0.41 1.0 






35.0 [22.0] 37.0 [59.0] 5.0 [21.0] <0.001  1.0 
Symptom 
duration (months) 
27.6 [29.0] 73.4 [86.8] NA <0.001 <0.001 
Cognition MMSE 28.0 [3.0] 27.0 [3.0] 28.5 [3.0] 0.056 1.0 
Depression BDI 5.0 [9.0] 7.0 [9.0] 0.5 [5.0] <0.001 1.0 
 
Glabellar reflex 
Score 21.0 [16.0] 12.0 [20.0] 0.0 [4.0] <0.001 0.088 




Caudate 2.14 (0.65) 3.11 (0.63) 2.58 (0.32) <0.001 <0.001 
Anterior putamen 1.62 (0.57) 3.01 (0.65) 2.49 (0.33) <0.001 <0.001 
Posterior 
putamen 
1.00 (0.41) 2.67 (0.57) 2.18 (0.32) <0.001 <0.001 
 
1 P-values are from ANOVA, chi-square test, Mann-Whitney U test or Kruskal-Wallis test. 









Table 2 Demographic and clinical characteristics of PD patients with a normal glabellar 
reflex (GR) result in relation to PD patients with an abnormal GR result; values are means 
(SD), medians [IQR] or n. 
 








n = 161 35 126 - 
Age (years) 61.7 (10.7) 65.3 (9.8) 0.063 






29.0 [57.0] 38.5 [63.0] 0.004 
Symptom duration 
(months) 
18.0 [24.0] 18.0 [26.0] 0.646 
Cognition MMSE 28.0 [3.0] 28.0 [4.0] 0.677 
Depression BDI 3.0 [7.0] 6.0 [8.0] 0.059 




Caudate 2.36 (0.71) 2.08 (0.62) 0.021 
Anterior putamen 1.82 (0.63) 1.57 (0.55) 0.022 
Posterior putamen 1.15 (0.43) 0.96 (0.40) 0.014 
 









































Fig. 2 Glabellar tap score and specific binding ratio of the PD, ET and HC groups (a) 
Glabellar tap scores (range 0-21) of the PD, ET and HC groups, with the median and IQR 
marked with horizontal lines; note that in the PD patients, the median was 21 and thus is 
not visible (b) Mean posterior putamen specific binding ratio (SBR) of the PD, ET and HC 
groups, with the mean and 95% CI marked with horizontal lines *** = p<0.001 
 
 
 
